- Home
- CISO vs FGEN Comparison
CISO vs FGEN Comparison
Compare CISO & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- FGEN
- Stock Information
- Founded
- CISO 2015
- FGEN 1993
- Country
- CISO United States
- FGEN United States
- Employees
- CISO N/A
- FGEN N/A
- Industry
- CISO Computer Software: Prepackaged Software
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- FGEN Health Care
- Exchange
- CISO Nasdaq
- FGEN Nasdaq
- Market Cap
- CISO 32.7M
- FGEN 34.5M
- IPO Year
- CISO N/A
- FGEN 2014
- Fundamental
- Price
- CISO $1.03
- FGEN $0.57
- Analyst Decision
- CISO
- FGEN
- Analyst Count
- CISO 0
- FGEN 0
- Target Price
- CISO N/A
- FGEN N/A
- AVG Volume (30 Days)
- CISO 312.9K
- FGEN 1.7M
- Earning Date
- CISO 11-18-2024
- FGEN 02-24-2025
- Dividend Yield
- CISO N/A
- FGEN N/A
- EPS Growth
- CISO N/A
- FGEN N/A
- EPS
- CISO N/A
- FGEN N/A
- Revenue
- CISO $54,633,909.00
- FGEN $180,015,000.00
- Revenue This Year
- CISO $78.76
- FGEN $22.05
- Revenue Next Year
- CISO N/A
- FGEN N/A
- P/E Ratio
- CISO N/A
- FGEN N/A
- Revenue Growth
- CISO 34.87
- FGEN 16.15
- 52 Week Low
- CISO $0.26
- FGEN $0.18
- 52 Week High
- CISO $3.84
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- CISO 36.83
- FGEN 57.36
- Support Level
- CISO $0.93
- FGEN $0.51
- Resistance Level
- CISO $1.39
- FGEN $0.76
- Average True Range (ATR)
- CISO 0.51
- FGEN 0.09
- MACD
- CISO -0.19
- FGEN -0.00
- Stochastic Oscillator
- CISO 3.30
- FGEN 33.26
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.